Hiroyuki Uchida, MD, PhD | Psychiatrist.com

Original Research

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

July 22, 2014

Hiroyoshi Takeuchi , Takefumi Suzuki , Robert R. Bies , et al

Original Research

Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data

May 15, 2014

Hiroyoshi Takeuchi , Gagan Fervaha , Hiroyuki Uchida , et al

Article

A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable: Implications for Dopamine D2 Receptor Occupancy During Maintenance Treatment in Schizophrenia

August 15, 2012

Saeko Ikai , Gary Remington , Takefumi Suzuki , et al

Article

How Successful Are Physicians in Eliciting the Truth From Their Patients? A Large-Scale Internet Survey From Patients' Perspectives

March 15, 2012

Norifusa Sawada , Hiroyuki Uchida , Koichiro Watanabe , et al

Original Research

Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms

December 16, 2009

Hiroyuki Uchida , David C. Mamo , Benoit H. Mulsant , et al

Letter to the Editor

Selective Serotonin Reuptake Inhibitor-Induced Spermatorrhea in 2 Patients

August 15, 2009

Shinichiro Nakajima , Hiroyuki Uchida , Takefumi Suzuki , et al

Original Research

Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia

August 31, 2008

Hiroyuki Uchida , David C. Mamo , Shitij Kapur , et al

Original Research

Quetiapine Extended-Release Versus Immediate-Release Formulation: A Positron Emission Tomography Study

January 15, 2008

David C. Mamo , Hiroyuki Uchida , Irina Vitcu , et al

« 1 2